Elisa María Espinosa-López
Research Subjects
Elisa María Espinosa-López has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Antonio López-Lozano
Departamento de Bioquímica y Biología Molecular, Campus de Excelencia Internacional Agroalimentario, Universidad de Córdoba, Córdoba 14014, Spain
1 shared publication - Beatriz Ortiz-Guisado1 shared publication
- Elisa Diez de Castro
Department of Animal Medicine and Surgery, University of Córdoba, Spain
1 shared publication - Escolastico Aguilera-Tejero
Department of Animal Medicine and Surgery, University of Cordoba, Campus Universitario Rabanales, Cordoba, Spain
1 shared publication - Guadalupe Gómez-Baena
Department of Biochemistry and Molecular Biology, Faculty of Veterinary Sciences, University of Córdoba, Córdoba, Spain
1 shared publication - Oriol Alberto Rangel-Zuñiga
Lipids and Atherosclerosis Unit, Internal Medicine Unit, Reina Sofia University Hospital, Córdoba, Spain
1 shared publication
Latest Publications
- Open Access
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Circulating microRNAs as potential predictive biomarkers of equine metabolic syndrome
Equine Metabolic Syndrome (EMS) is a complex endocrine disorder characterized by obesity, insulin dysregulation (ID), and an increased risk of developing laminitis. Despite growing awareness of EMS, early and accurate diagnosis remains challenging. In this study, we investigated changes in the levels of circulating microRNAs (miRNAs) in plasma samples from horses diagnosed with EMS, compared to obese non-ID horses and healthy controls. Using a targeted real-time PCR OpenArray, we identified four miRNAs —miR-221, miR-186, miR-132, and miR-15a— that were differentially expressed across the groups. Functional enrichment analysis of their validated target genes revealed involvement in key insulin signalling mechanisms, including phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT), AMP-activated protein kinase (AMPK) and forkhead box O protein (FOXO) signalling pathways. Receiver Operating Characteristic (ROC) curve analysis demonstrated that combinations of these miRNAs provided discriminatory power between clinical groups (AUCs ranging from 0.79 to 0.93). These findings support the potential of circulating miRNA levels as non-invasive predictive biomarkers for EMS and related metabolic dysfunctions. Moreover, the signalling pathways identified provide mechanistic insight and establish a foundation for future studies aimed at therapeutic target discovery.
- 6 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCirculating microRNAs as potential predictive biomarkers of equine metabolic syndrome
Equine Metabolic Syndrome (EMS) is a complex endocrine disorder characterized by obesity, insulin dysregulation (ID), and an increased risk of developing laminitis. Despite growing awareness of EMS, early and accurate diagnosis remains challenging. In this study, we investigated changes in the levels of circulating microRNAs (miRNAs) in plasma samples from horses diagnosed with EMS, compared to obese non-ID horses and healthy controls. Using a targeted real-time PCR OpenArray, we identified four miRNAs —miR-221, miR-186, miR-132, and miR-15a— that were differentially expressed across the groups. Functional enrichment analysis of their validated target genes revealed involvement in key insulin signalling mechanisms, including phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT), AMP-activated protein kinase (AMPK) and forkhead box O protein (FOXO) signalling pathways. Receiver Operating Characteristic (ROC) curve analysis demonstrated that combinations of these miRNAs provided discriminatory power between clinical groups (AUCs ranging from 0.79 to 0.93). These findings support the potential of circulating miRNA levels as non-invasive predictive biomarkers for EMS and related metabolic dysfunctions. Moreover, the signalling pathways identified provide mechanistic insight and establish a foundation for future studies aimed at therapeutic target discovery.